Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

Ez Soliman, S. Sharma, K. Arastéh, D. Wohl, A. Achhra, G. Tambussi, J. O'Connor, Jh Stein, Da Duprez, Jd Neaton, A. Phillips

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: The Strategic Timing of AntiRetroviral Treatment (START) trial has recruited antiretroviral-naïve individuals with high CD4 cell counts from all regions of the world. We describe the distribution of cardiovascular disease (CVD) risk factors, overall and by geographical region, at study baseline. Methods: The distribution of CVD risk factors was assessed and compared by geographical region among START participants who had a baseline electrocardiogram (n=4019; North America, 11%; Europe/Australia/Israel, 36%; South America, 26%; Asia, 4%; Africa, 23%; median age 36 years; 26% female). Results: About 58.3% (n=2344) of the participants had at least one CVD risk factor and 18.9% (n=761) had two or more. The most common CVD risk factors were current smoking (32%), hypertension (19.3%) and obesity (16.5%). There were significant differences in the prevalence of CVD risk factors among geographical regions. The prevalence of at least one risk factor across regions was as follows: North America, 70.0%; Europe/Australia/Israel, 65.1%; South America, 49.4%; Asia, 37.0%; Africa, 55.8% (P-value

Original languageEnglish
Pages (from-to)46-54
Number of pages9
JournalHIV Medicine
Volume16
Issue numberS1
DOIs
Publication statusPublished - Apr 1 2015

Keywords

  • Cardiovascular risk
  • HIV
  • Strategic Timing of AntiRetroviral Treatment (START) trial

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Health Policy

Fingerprint Dive into the research topics of 'Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial'. Together they form a unique fingerprint.

Cite this